Cargando…

A Fluorescent Kinase Inhibitor that Exhibits Diagnostic Changes in Emission upon Binding

The development of a fluorescent LCK inhibitor that exhibits favourable solvatochromic properties upon binding the kinase is described. Fluorescent properties were realised through the inclusion of a prodan‐derived fluorophore into the pharmacophore of an ATP‐competitive kinase inhibitor. Fluorescen...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleming, Cassandra L., Sandoz, Patrick A., Inghardt, Tord, Önfelt, Björn, Grøtli, Morten, Andréasson, Joakim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851755/
https://www.ncbi.nlm.nih.gov/pubmed/31411364
http://dx.doi.org/10.1002/anie.201909536
_version_ 1783469679332818944
author Fleming, Cassandra L.
Sandoz, Patrick A.
Inghardt, Tord
Önfelt, Björn
Grøtli, Morten
Andréasson, Joakim
author_facet Fleming, Cassandra L.
Sandoz, Patrick A.
Inghardt, Tord
Önfelt, Björn
Grøtli, Morten
Andréasson, Joakim
author_sort Fleming, Cassandra L.
collection PubMed
description The development of a fluorescent LCK inhibitor that exhibits favourable solvatochromic properties upon binding the kinase is described. Fluorescent properties were realised through the inclusion of a prodan‐derived fluorophore into the pharmacophore of an ATP‐competitive kinase inhibitor. Fluorescence titration experiments demonstrate the solvatochromic properties of the inhibitor, in which dramatic increase in emission intensity and hypsochromic shift in emission maxima are clearly observed upon binding LCK. Microscopy experiments in cellular contexts together with flow cytometry show that the fluorescence intensity of the inhibitor correlates with the LCK concentration. Furthermore, multiphoton microscopy experiments demonstrate both the rapid cellular uptake of the inhibitor and that the two‐photon cross section of the inhibitor is amenable for excitation at 700 nm.
format Online
Article
Text
id pubmed-6851755
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68517552019-11-18 A Fluorescent Kinase Inhibitor that Exhibits Diagnostic Changes in Emission upon Binding Fleming, Cassandra L. Sandoz, Patrick A. Inghardt, Tord Önfelt, Björn Grøtli, Morten Andréasson, Joakim Angew Chem Int Ed Engl Communications The development of a fluorescent LCK inhibitor that exhibits favourable solvatochromic properties upon binding the kinase is described. Fluorescent properties were realised through the inclusion of a prodan‐derived fluorophore into the pharmacophore of an ATP‐competitive kinase inhibitor. Fluorescence titration experiments demonstrate the solvatochromic properties of the inhibitor, in which dramatic increase in emission intensity and hypsochromic shift in emission maxima are clearly observed upon binding LCK. Microscopy experiments in cellular contexts together with flow cytometry show that the fluorescence intensity of the inhibitor correlates with the LCK concentration. Furthermore, multiphoton microscopy experiments demonstrate both the rapid cellular uptake of the inhibitor and that the two‐photon cross section of the inhibitor is amenable for excitation at 700 nm. John Wiley and Sons Inc. 2019-09-05 2019-10-14 /pmc/articles/PMC6851755/ /pubmed/31411364 http://dx.doi.org/10.1002/anie.201909536 Text en © 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Communications
Fleming, Cassandra L.
Sandoz, Patrick A.
Inghardt, Tord
Önfelt, Björn
Grøtli, Morten
Andréasson, Joakim
A Fluorescent Kinase Inhibitor that Exhibits Diagnostic Changes in Emission upon Binding
title A Fluorescent Kinase Inhibitor that Exhibits Diagnostic Changes in Emission upon Binding
title_full A Fluorescent Kinase Inhibitor that Exhibits Diagnostic Changes in Emission upon Binding
title_fullStr A Fluorescent Kinase Inhibitor that Exhibits Diagnostic Changes in Emission upon Binding
title_full_unstemmed A Fluorescent Kinase Inhibitor that Exhibits Diagnostic Changes in Emission upon Binding
title_short A Fluorescent Kinase Inhibitor that Exhibits Diagnostic Changes in Emission upon Binding
title_sort fluorescent kinase inhibitor that exhibits diagnostic changes in emission upon binding
topic Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851755/
https://www.ncbi.nlm.nih.gov/pubmed/31411364
http://dx.doi.org/10.1002/anie.201909536
work_keys_str_mv AT flemingcassandral afluorescentkinaseinhibitorthatexhibitsdiagnosticchangesinemissionuponbinding
AT sandozpatricka afluorescentkinaseinhibitorthatexhibitsdiagnosticchangesinemissionuponbinding
AT inghardttord afluorescentkinaseinhibitorthatexhibitsdiagnosticchangesinemissionuponbinding
AT onfeltbjorn afluorescentkinaseinhibitorthatexhibitsdiagnosticchangesinemissionuponbinding
AT grøtlimorten afluorescentkinaseinhibitorthatexhibitsdiagnosticchangesinemissionuponbinding
AT andreassonjoakim afluorescentkinaseinhibitorthatexhibitsdiagnosticchangesinemissionuponbinding
AT flemingcassandral fluorescentkinaseinhibitorthatexhibitsdiagnosticchangesinemissionuponbinding
AT sandozpatricka fluorescentkinaseinhibitorthatexhibitsdiagnosticchangesinemissionuponbinding
AT inghardttord fluorescentkinaseinhibitorthatexhibitsdiagnosticchangesinemissionuponbinding
AT onfeltbjorn fluorescentkinaseinhibitorthatexhibitsdiagnosticchangesinemissionuponbinding
AT grøtlimorten fluorescentkinaseinhibitorthatexhibitsdiagnosticchangesinemissionuponbinding
AT andreassonjoakim fluorescentkinaseinhibitorthatexhibitsdiagnosticchangesinemissionuponbinding